ATTENTION ALL ROS1+ CANCER PATIENTS! Canadian ROS1 patients need our help ASAP!


Lung Cancer Canada is collecting data to support approval of crizotinib for ROS1+ non-small cell lung cancer in their country. Their deadline for submission is rapidly approaching, and they need more data to strengthen their case. They would like ROS1+ patients who have taking crizotinib to share the following information (no names): Demographic data (e.g., … Continue reading ATTENTION ALL ROS1+ CANCER PATIENTS! Canadian ROS1 patients need our help ASAP!

Crizotinib may be effective again after chemo


Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. This case is a proof of concept that re-challenging with crizotinib after intervening chemotherapy is feasible in ROS1-rearranged NSCLC with acquired resistance. Read full article here.

Pfizer new lung cancer drug is successful for funding.


NICE have published a guidance for Pfizer’s Xalkori drug to treat ROS1-postivie non-small cell lung cancer has been made available via the Cancer drugs fund. Head of Oncology at Pfizer UK Craig Eagle commented on the news, “The decision to make the drug available is good news for patients in England. We are committed to … Continue reading Pfizer new lung cancer drug is successful for funding.

The value of oncogene-focused patient-caregiver groups


Thanks to Dr. H. Jack West for the shout-out to our ros1cancer.com website and our page Drugs to Treat ROS1+ Cancer! Time to highlight that we are now in an era when pts w/rare cancers are increasingly likely to know more than docs, even very good ones, about their dzs. This @ros1cancer page on Drugs … Continue reading The value of oncogene-focused patient-caregiver groups

Two Colorado studies find resistance mechanisms in ALK+ and ROS1+ cancers


“A University of Colorado Cancer Center study published today in the journal Clinical Cancer Research provides an in-depth look at how these ALK+ and ROS1+ cancers evolve to resist treatment. A second study demonstrates the ability to identify these changes in patient blood samples, perhaps easing the ability to monitor patients for these changes that … Continue reading Two Colorado studies find resistance mechanisms in ALK+ and ROS1+ cancers

ROS1ders Meet the Rodents


What happens when you tell someone they have a terminal diagnosis and potentially less than a year to live? They cry, get scared, worry about the loved ones they will leave behind, and grieve. And if they are anything like the ROS1ders, they organize and make stuff happen. It has not been easy, and along … Continue reading ROS1ders Meet the Rodents